Indian Opioid Addiction market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
The factors leading to the growth of the market in the region are high demand for opioid drugs due to the high incidence of cancer and chronic pain patients, and less regulatory control on opioid drugs. In India, there is a steady rise in prescription opioids. India found that in 2018, 2.1 per cent of the population aged 10-75 years, a total of 23 million people, had used opioids in the past year. Among opioids, heroin is the most prevalent substance among the surveyed population followed by the non-medical use of pharmaceutical opioids and opium. Buprenorphine, morphine, pentazocine and tramadol are the most common opioids misused in India. India had traditionally exported much of its opioid production. The country is a major producer of pharmaceuticals such as tramadol and fentanyl.
Opioids play a vital role in alleviating the pain of patients suffering from such conditions. The major factors driving the market growth include the increasing prevalence of diseases that cause chronic pain, such as cancer, arthritis, lower back pain, fibromyalgia and postsurgical pain, inclination toward extended release formulations from immediate release of opioids and the rising population affected with chronic disorders, along with favourable reimbursement scenarios, is driving the growth of the market.